biodesix develops and commercializes blood-based molecular diagnostic tests that advance the standard of care in oncology. our diagnostics help patients and their doctors make more informed decisions about treatment based on a patient's unique molecular profile. we're advancing precision medicine by helping physicians provide the right patient with the right treatment at the right time, and move patients to optimal treatment faster. we partner with pharmaceutical companies to develop tests that accelerate pipelines and bring effective therapies to market. our two commercialized tests, veristrat® & genestrat™, offer results in 72 hours. no tissue is required.
Company profile
Ticker
BDSX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
203986492
BDSX stock data
Latest filings (excl ownership)
S-1/A
IPO registration (amended)
24 May 24
8-K
Submission of Matters to a Vote of Security Holders
23 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management
8 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-1
IPO registration
23 Apr 24
PRE 14A
Preliminary proxy
16 Apr 24
8-K
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
9 Apr 24
Transcripts
BDSX
Earnings call transcript
2024 Q1
8 May 24
BDSX
Earnings call transcript
2023 Q4
1 Mar 24
BDSX
Earnings call transcript
2023 Q3
7 Nov 23
BDSX
Earnings call transcript
2023 Q2
7 Aug 23
BDSX
Earnings call transcript
2023 Q2
7 Aug 23
BDSX
Earnings call transcript
2023 Q1
11 May 23
BDSX
Earnings call transcript
2022 Q4
6 Mar 23
BDSX
Earnings call transcript
2022 Q3
6 Nov 22
BDSX
Earnings call transcript
2022 Q2
6 Aug 22
BDSX
Earnings call transcript
2022 Q1
11 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.58 mm | 11.58 mm | 11.58 mm | 11.58 mm | 11.58 mm | 11.58 mm |
Cash burn (monthly) | 4.93 mm | 1.15 mm | 3.67 mm | 3.00 mm | 5.10 mm | 2.54 mm |
Cash used (since last report) | 8.97 mm | 2.09 mm | 6.69 mm | 5.46 mm | 9.29 mm | 4.62 mm |
Cash remaining | 2.60 mm | 9.49 mm | 4.89 mm | 6.12 mm | 2.29 mm | 6.95 mm |
Runway (months of cash) | 0.5 | 8.3 | 1.3 | 2.0 | 0.4 | 2.7 |
Institutional ownership, Q1 2024
50.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 10 |
Opened positions | 3 |
Closed positions | 0 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 1.60 bn |
Total shares | 58.17 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Schuler Jack W | 30.58 mm | $49.54 mm |
Kennedy Lawrence T. Jr | 10.53 mm | $17.06 mm |
Hirschman Orin | 5.57 mm | $7.24 mm |
Patience John | 4.61 mm | $7.47 mm |
Manlia | 3.65 mm | $4.75 mm |
Life Sciences Alternative Funding | 2.19 mm | $44.16 mm |
Essex Investment Management | 925.61 k | $1.32 bn |
Allworth Financial | 99.33 k | $142.04 mm |
Commonwealth Equity Services | 16.31 k | $23.00 k |
Simplex Trading | 1.07 k | $1.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 May 24 | Scott Hutton | Common Stock | Option exercise | Acquire M | No | No | 0 | 26,120 | 0.00 | 509,900 |
23 May 24 | Scott Hutton | Series A Non-Voting Convertible Preferred Stock Common Stock | Option exercise | Dispose M | No | No | 0 | 653 | 0.00 | 0 |
23 May 24 | Chris Vazquez | Common Stock | Option exercise | Acquire M | No | No | 0 | 880 | 0.00 | 10,795 |
23 May 24 | Chris Vazquez | Series A Non-Voting Convertible Preferred Stock Common Stock | Option exercise | Dispose M | No | No | 0 | 22 | 0.00 | 0 |
23 May 24 | Gary Anthony Pestano | Common Stock | Option exercise | Acquire M | No | No | 0 | 880 | 0.00 | 125,128 |
23 May 24 | Gary Anthony Pestano | Series A Non-Voting Convertible Preferred Stock Common Stock | Option exercise | Dispose M | No | No | 0 | 22 | 0.00 | 0 |
23 May 24 | Kieran O'Kane | Common Stock | Option exercise | Acquire M | No | No | 0 | 13,080 | 0.00 | 88,604 |
23 May 24 | Kieran O'Kane | Series A Non-Voting Convertible Preferred Stock Common Stock | Option exercise | Dispose M | No | No | 0 | 327 | 0.00 | 0 |
21 May 24 | Franchi Jean M. | Stock Options Common Stock | Grant | Acquire A | No | No | 1.57 | 37,050 | 58.17 k | 37,050 |
21 May 24 | Franchi Jean M. | RSU Common Stock | Grant | Acquire A | No | No | 0 | 60,766 | 0.00 | 60,766 |
News
TD Cowen Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $2.8
13 May 24
Biodesix Q1 2024 GAAP EPS $(0.14), Inline, Sales $14.818M Beat $14.180M Estimate
8 May 24
Lake Street Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $3
3 May 24
Biodesix Plans To Present New Data On Liquid Biopsy Technologies At AACR 2024 Annual Meeting
9 Apr 24
S&P 500 Gains Over 1%; GCT Semiconductor Shares Spike Higher
5 Apr 24
Press releases
Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting
21 May 24
Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management
8 May 24
Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference
7 May 24
Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024
24 Apr 24
Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting
9 Apr 24